75 results
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
receptor type 2, or CB2 receptor, agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
several innovative immunotherapy products and SciSparc’s own patents in the immunotherapy field. In August 2015, the Company decided to adopt … , developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic
6-K
EX-99.1
SPRC
SciSparc Ltd
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
the Company’s recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling … involved in the clinical trial. This achievement represents a pivotal moment for SciSparc as we introduce SCI-210, an innovative cannabinoid-based treatment
6-K
EX-99.1
SPRC
SciSparc Ltd
29 Feb 24
Report of Foreign Private Issuer
9:07am
completed the manufacturing of and delivered its innovative SCI- 210 treatment, in accordance with its initiation of enrollment for the clinical trial
F-1
jd1nzjy 2p6nuo4ncr8h
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
h2w0l2wzzi2
28 Nov 23
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
4:00pm
6-K
EX-99.1
af7j65j6 2fcf
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.2
he6c3y0k3ehf12ftr
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.1
n6c1jjhevj
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.2
zfmoz iawzi3
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
opbsugn0
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
tkzjsaxjt g8o9ejl
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
8sagyh0reph7fv9h9q
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
29sls0gd3s7ofp 6w
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
pern lac9
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.2
i7nyhaish b41zc5
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
08c6h5vfbmk0vdrfy
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
hh6s1e8zmq
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am